2025-10-19 - Analysis Report
Okay, here's an analysis of Natera (NTRA), incorporating all the provided data points.

**Report: Natera Inc. (NTRA) Analysis**

**Company Overview:** Natera Inc. is a genetic testing company focused on reproductive health, oncology, and organ health.

**1. Performance vs. S&P 500 (VOO)**

*   **NTRA Cumulative Return:** 87.80%
*   **VOO Cumulative Return:** 97.31%
*   **Absolute Deviation:** -18.1 (NTRA is lagging VOO by 18.1 percentage points in cumulative return).
*   **Relative Deviation:** 26.7 (NTRA's current deviation relative to its historical deviation range).

**Analysis:** NTRA has underperformed the S&P 500. The relative deviation suggests that NTRA is currently positioned in the lower end of its historical deviation range compared to VOO.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
| ---------- | ------- | ----- | ------- | ----- | ------ |
| 2015-2017  | -10.0%  | 70.1% | -34.0%  | -0.2  | 1.2    |
| 2016-2018  | 22.0%   | 80.0% | 6.0%    | 0.1   | 1.9    |
| 2017-2019  | 50.0%   | 80.0% | 28.0%   | 1.0   | 4.6    |
| 2018-2020  | 186.0%  | 80.5% | 163.0%  | 1.1   | 13.7   |
| 2019-2021  | 96.0%   | 80.5% | 49.0%   | 1.6   | 12.8   |
| 2020-2022  | -77.0%  | 80.5% | -76.0%  | 0.1   | 5.5    |
| 2021-2023  | -194.0% | 76.6% | -195.0% | -1.1  | 8.6    |
| 2022-2024  | 8.0%    | 76.6% | -13.0%  | -1.2  | 21.7   |
| 2023-2025  | 115.0%  | 76.6% | 53.0%   | 0.1   | 24.9   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** The CAGR has fluctuated significantly, showcasing periods of high growth and substantial decline.
*   **MDD (Maximum Drawdown):** High MDD values consistently indicate significant downside risk.
*   **Alpha:** Alpha is inconsistent, with periods of strong outperformance (positive alpha) followed by periods of significant underperformance (negative alpha).
*   **Beta:** Beta values vary, indicating fluctuating sensitivity to market movements. Periods with beta close to 1 suggest market-like sensitivity, while values above 1 indicate higher volatility.
*   **Cap(B):** Market capitalization has grown over time, indicating company expansion despite performance volatility.

**2. Recent Stock Price Movements**

*   **Current Price:** 181.69
*   **Previous Close:** 180.54
*   **Change:** 0.64
*   **5-Day Moving Average:** 177.726
*   **20-Day Moving Average:** 169.3605
*   **60-Day Moving Average:** 162.6764

**Analysis:**

The stock price is above its 5, 20, and 60-day moving averages, indicating a short-term upward trend.  The recent change is relatively small (0.64), suggesting no major immediate price shock from the last market close.

**3. Market Risk Indicators and Return Expectations**

*   **MRI (Market Risk Indicator):** 0.5 (Low Investment Recommended)
*   **RSI (Relative Strength Index):** 79.39 (Overbought)
*   **PPO (Percentage Price Oscillator):** 0.8025
*   **Hybrid Signal:** Buy 100% of cash (6 shares - Very Safe - MRI:0.90)
*   **Delta_Previous_Relative_Divergence (20-day change):** 2.4 (+) - Short-term increase.
*   **Expected Return:** -128.9% (Significant underperformance vs. S&P 500 over the long term if investing from the current point).

**Analysis:**

*   The MRI suggests a low investment recommendation, indicating moderate risk.
*   The RSI indicates that the stock is currently overbought. This often precedes a price correction.
*   The Hybrid Signal is conflicting, recommending a buy despite the MRI. This might be based on a specific proprietary model.
*   The positive change in relative divergence indicates a recent short-term increase in the stock's performance relative to its historical pattern.
*   The extremely negative expected return is a major red flag, suggesting the model predicts significant long-term underperformance compared to the S&P 500.

**4. Recent News & Significant Events**

*   **Fast Company Recognition:** Natera was named to Fast Company’s Next Big Things in Tech list, suggesting innovation recognition.
*   **Signatera Study Validation:** A study published in JCO PO showed Signatera's superior prognostic value in testicular cancer.
*   **Investor Call:** Natera will host an investor call to discuss ESMO findings, potentially impacting investor sentiment.
*   **Valuation Analysis:**  Articles explore Natera's valuation and long-term potential, acknowledging recent performance.

**Analysis:**

Recent news is a mix of positive and neutral. The Fast Company recognition and the positive study results for Signatera could be bullish. The investor call is a potential catalyst, and valuation discussions suggest ongoing market interest in the company's long-term prospects.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.53)
*   **Target Price:** Average: 193.95 / High: 235.00 / Low: 37.00

**Analysis:**

The analyst consensus is generally positive, with a "Buy" rating. The average target price suggests potential upside from the current price. However, the wide range between the high and low target prices indicates significant disagreement among analysts regarding the stock's future value.  The lack of information about the Recent Rating Changes makes this section less informative.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
| ---------- | ----- | --------- |
| 2025-08-08 | -0.74 | 0.55 B$   |
| 2025-05-09 | -0.5  | 0.50 B$   |
| 2024-11-12 | -0.26 | 0.44 B$   |
| 2024-08-09 | -0.3  | 0.41 B$   |
| 2025-08-08 | -0.3  | 0.41 B$   |

**Analysis:**

*   The company is consistently reporting negative Earnings Per Share (EPS), indicating losses.
*   Revenue has generally been increasing over the reported period, although there appears to be a typo.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-06-30 | \$0.55B  | 63.41%        |
| 2025-03-31 | \$0.50B  | 63.12%        |
| 2024-12-31 | \$0.48B  | 62.94%        |
| 2024-09-30 | \$0.44B  | 61.79%        |
| 2024-06-30 | \$0.41B  | 58.83%        |

Capital and Profitability:

| Quarter    | Equity    | ROE       |
| ---------- | --------- | --------- |
| 2025-06-30 | \$1.25B  | -8.10%    |
| 2025-03-31 | \$1.24B  | -5.40%    |
| 2024-12-31 | \$1.20B  | -4.50%    |
| 2024-09-30 | \$0.88B  | -3.60%    |
| 2024-06-30 | \$0.84B  | -4.48%    |

**Analysis:**

*   **Revenue:**  Revenue shows a positive trend, indicating sales growth.
*   **Profit Margin:**  The profit margin is very high and relatively stable. This is a positive sign, although it should be considered in the context of the overall business model and expenses.
*   **Equity:**  Equity is increasing, suggesting that the company is retaining earnings or raising capital effectively.
*   **ROE (Return on Equity):**  ROE is negative, reflecting the company's losses. Although the trend has become increasingly negative, it does align with what the historical data showed

**7. Overall Summary**

Natera (NTRA) presents a mixed picture. The company is experiencing revenue growth and has high profit margins.  Recent news events are moderately positive. Analyst ratings are generally "Buy," with a substantial average target price.

However, there are significant concerns:

*   **Underperformance vs. S&P 500:** NTRA has underperformed the broader market.
*   **Negative Earnings:** The company is consistently losing money (negative EPS and ROE).
*   **High Risk:** The MRI suggests only a low investment recommendation.
*   **Conflicting Signals:** The Hybrid Signal contradicts the MRI.
*   **Negative Expected Return:** The model predicts significant long-term underperformance.
*   **Overbought:** RSI indicates that the stock is currently overbought.

**Conclusion:**

While Natera shows promise in terms of revenue growth and analyst sentiment, the persistent losses, underperformance, and high risk indicators warrant caution.  The extremely negative expected return is a critical concern.  A thorough investigation of the company's expense structure, path to profitability, and the assumptions underlying the negative return forecast is crucial before considering an investment.
